We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma has reached a major milestone in its development in January 2025, with positive topline results from its Phase 3 clinical trial evaluating its microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Enhancing Survival Through Innovative Immune Modulation
We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.
See News
Corporate profile
Press Releases
February 3, 2026: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
January 20, 2026: MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
December 8, 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
Media Coverage
November 28, 2025: French Tech : Maat Pharma, un anticancer issu du microbiote – BFM Business (French Only)
October 30, 2025: Éric Soyer – Directeur Financier MAAT PHARMA : Stratégie & actualités – Lyon Place Financière (French Only)
August 7, 2025: French Tech : Maat Pharma traite les complications de greffe de moelle osseuse – BFM Business (French Only)
Posters
MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study
MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice
MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity
